top of page
Medications for the treatment of pulmonary arterial hypertension
PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read...
PHA Canada
Aug 10, 20221 min read
Advances in Pulmonary Hypertension: Quality of Life
About Advances in Pulmonary Hypertension magazine: Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension...
PHA Canada
Jul 10, 20221 min read
Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications
Clinicians at 17 US pulmonary hypertension centres were interviewed about their understanding of social determinants of health in...
PHA Canada
Jul 8, 20221 min read
Inhaled Seralutinib Shows Promise in 2 PAH Animal Models
This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...
PHA Canada
Jun 14, 20221 min read
Opsyvni enters pCPA negotiations
In February, the panCanadian Pharmaceutical Alliance entered into formal pricing negotiations with the manufacturer of Opsyvni...
PHA Canada
Mar 28, 20221 min read
Social Media Participation Among Parents and Caregivers of Children With Pulmonary Hypertension
This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...
PHA Canada
Mar 15, 20221 min read
Palliative Care and Pulmonary Arterial Hypertension
In other diseases, palliative care is associated with better quality of life, symptom management, illness understanding, and reduced...
PHA Canada
Mar 15, 20221 min read
BET Protein Inhibition for Pulmonary Arterial Hypertension
This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating...
PHA Canada
Mar 14, 20221 min read
bottom of page